Monthly ReportAug 1–31, 2026
Sepsis, August 2026 edition
We read 728 papers and selected 5.
Summary
Sepsis research in August 2026 continued a decisive shift from nonspecific syndrome-based management toward precision medicine guided by host biology, organ-specific mechanisms, and clinical phenotypes. Major therapeutic advances were predominantly preclinical, including macrophage-centered regulation through TG2-vimentin and PARP7-TBK1 pathways, as well as epigenetic control of kidney injury through the DDX3x-histone lactylation-NINJ1 axis. Diagnostic development progressed through rapid direct-from-blood pathogen identification with antimicrobial susceptibility testing, pediatric phenotype-based risk stratification, and dynamic immune or organ-function monitoring. Clinical studies also addressed post-sepsis vaccination and early vasopressor timing, but prospective validation and implementation trials remain necessary before broad practice changes. After normalization to a common 0-100 scale and recency weighting, the highest-ranked papers were concentrated in the final week, reflecting both strong study scores and the greater weight assigned to later evidence.
Selected Articles
1. Microbiota-derived isovalerate ameliorates sex-specific gut barrier dysfunction in malnutrition.
Using specific pathogen-free and germ-free mice, targeted metabolomics, and human-derived colonoid monolayers, this study identified branched-chain fatty acids, particularly isovalerate, as regulators of intestinal barrier integrity. Isovalerate administration and leucine supplementation restored claudin-8 localization and reduced gut permeability in malnourished male mice, linking dysbiosis, barrier failure, bacterial translocation, and sepsis risk.
Impact: The study identifies a specific microbiota-derived metabolite and a dietary precursor as experimentally tractable approaches to malnutrition-associated barrier failure, a major pathway for bacterial translocation and sepsis.
Clinical Implications: Leucine supplementation or targeted isovalerate delivery could eventually be tested in malnourished patients at risk of infection, but human dosing, safety, microbiome dependence, and sex-specific effects must first be established.
Key Findings
- Malnutrition increased colonic permeability and bacterial translocation in male specific pathogen-free mice.
- Isovalerate improved epithelial barrier function in human-derived colonoid monolayers.
- Isovalerate or leucine restored claudin-8 localization and reduced permeability in malnourished male mice.
2. Transglutaminase 2 regulates vimentin-dependent proteostasis during macrophage activation.
This mechanistic study identified transglutaminase 2 (TG2) as a driver of sepsis-associated liver inflammation and multiorgan injury. TG2 cross-linked vimentin in macrophages, promoting cytoskeletal remodeling and sustained inflammatory signaling. Genetic deletion or pharmacological inhibition of TG2 improved survival and reduced inflammation in septic mice.
Impact: The study reveals a previously underrecognized link between cytoskeletal proteostasis and macrophage inflammation and demonstrates therapeutic benefit from TG2 inhibition in vivo. It offers a concrete mechanism-based strategy beyond nonspecific anti-inflammatory treatment.
Clinical Implications: TG2 inhibition could become a candidate treatment for sepsis-associated liver dysfunction and systemic inflammation, but human target engagement, safety, dosing, and timing must be established before translation.
Key Findings
- TG2 activity increased in macrophages and promoted liver inflammation in septic mice.
- TG2 cross-linked vimentin, while genetic or pharmacological TG2 inhibition improved survival and reduced multiorgan inflammation.
- The TG2-vimentin pathway linked macrophage proteostasis to systemic organ injury.
3. Rapid and robust diagnosis of bloodstream infections by single-cell analysis.
The STREAM platform enriched pathogens directly from whole blood and combined single-cell identification with antimicrobial susceptibility testing. It achieved 96.15% concordance for pathogen identification, high susceptibility agreement across 219 drug-dose combinations, and complete results within 6.75–17 hours, with detection limits as low as 0.1–1 CFU/ml.
Impact: The platform addresses the major diagnostic delay of conventional blood culture by offering rapid pathogen identification and susceptibility information directly from blood. If validated in routine suspected-sepsis populations, it could accelerate targeted treatment and reduce unnecessary broad-spectrum antibiotics.
Clinical Implications: STREAM may complement conventional blood culture and support earlier antimicrobial narrowing, particularly when prior antibiotics reduce culture yield. Prospective studies must establish effects on time to effective therapy, antibiotic exposure, resistance, and mortality.
Key Findings
- Pathogen identification showed 96.15% concordance with clinical laboratory results.
- Complete diagnostic results were available within 6.75–17 hours, with detection limits of 0.1–1 CFU/ml.
- The platform simultaneously provided pathogen identification and antimicrobial susceptibility information from whole blood.
4. Macrophage PARP7 Alleviates Septic Cardiomyopathy by Interacting With TBK1 and Suppressing TBK1-Driven Inflammatory Response.
This study identified a macrophage-specific PARP7-TBK1 regulatory axis that limits inflammation in septic cardiomyopathy. PARP7 deficiency worsened cardiac injury, whereas macrophage-targeted AAV9-mediated PARP7 expression was cardioprotective in lipopolysaccharide and cecal ligation and puncture mouse models.
Impact: The work moves beyond descriptive inflammation by defining a cell-specific molecular brake and validating it with targeted gene delivery in two sepsis models. It provides a coherent therapeutic concept for septic cardiomyopathy, which currently lacks targeted treatments.
Clinical Implications: Enhancing macrophage PARP7 could eventually help prevent or treat septic cardiac dysfunction, but delivery specificity, immunogenicity, dosing, pathogen control, and safety require extensive validation before clinical translation.
Key Findings
- PARP7 deficiency exacerbated septic cardiomyopathy, while macrophage-specific PARP7 expression was cardioprotective.
- PARP7 interacted with TBK1 through ADP-ribosylation and reduced TBK1-driven inflammation in two murine sepsis models.
- Targeted macrophage PARP7 modulation improved experimental cardiac injury associated with sepsis.
5. DDX3x Regulates NINJ1 Transcription via Histone Lactylation in Sepsis Associated-Acute Kidney Injury.
This mechanistic study identified a DDX3x-histone lactylation-NINJ1 pathway linking lactate accumulation to PANoptosis and tubular injury in sepsis-associated acute kidney injury. DDX3x functioned as a previously unrecognized delactylase, and its agonist Odetiglucan reduced histone lactylation, NINJ1 transcription, PANoptosis, and kidney injury in cultured renal cells and cecal ligation and puncture mice.
Impact: The paper provides a multilevel causal mechanism and pharmacologic proof of concept for a major sepsis complication. It identifies an actionable epigenetic pathway rather than merely describing an inflammatory association.
Clinical Implications: DDX3x-enhancing therapies could eventually become targeted treatment for sepsis-associated acute kidney injury, but Odetiglucan requires validation of pharmacokinetics, safety, organ selectivity, therapeutic timing, and efficacy in larger models before human trials.
Key Findings
- Lactate-induced H3K9/18/27 histone lactylation increased NINJ1 transcription and PANoptosis.
- DDX3x was identified as a delactylase regulating histone lactylation and NINJ1 expression.
- Odetiglucan reduced kidney injury in cellular and murine sepsis-associated acute kidney injury models.